A Comprehensive Overview of the Role of Azacitidine in the Management of Myelodysplastic Syndromes and Acute Myeloid Leukaemia

European Oncology and Haematology - United Kingdom
doi 10.17925/eoh.2014.10.2.89
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Touch Medical Media, Ltd.

Related search

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Frontiers in Oncology
Cancer ResearchOncology
2019English

Epigenetic Approaches in the Treatment of Myelodysplastic Syndromes: Clinical Utility of Azacitidine

OncoTargets and Therapy
OncologyPharmacology
2010English

Evaluation of Azacitidine in Patients With Transplant‑ineligible Myelodysplastic Syndromes and Acute Myeloid Leukemia With Myelodysplasia‑related Changes in a Japanese Clinical Setting

Oncology Letters
Cancer ResearchOncology
2019English

CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Cost-Effectiveness in Canada of Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndromes

Current Oncology
Oncology
2013English

Coffee and Green Tea Consumption and Subsequent Risk of Acute Myeloid Leukemia and Myelodysplastic Syndromes in Japan

International Journal of Cancer
Cancer ResearchOncology
2017English

Atypical Chronic Myeloid Leukaemia – A Rare Subtype of Myelodysplastic/Myeloproliferative Neoplasm

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2018English

Correction: Mutations in the DNA Methylation Pathway and Number of Driver Mutations Predict Response to Azacitidine in Myelodysplastic Syndromes

Oncotarget
Oncology
2018English

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

PLoS ONE
Multidisciplinary
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy